Justlina-M Forte Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Justlina-M Forte is prescribed as an adjunct to diet and exercise to improve glycemic parameters such as fasting blood glucose and HbA1c levels. It is particularly beneficial for patients inadequately controlled on metformin monotherapy or those requiring combination therapy to minimize the risk of hypoglycemia and weight gain. Dosage adjustments may be necessary in patients with renal or hepatic impairment. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Linagliptin is generally well tolerated. Regular monitoring of blood glucose and renal function is recommended during therapy to ensure safety and efficacy.